Although not labeled as such by the FDA, TMS is considered a third line treatment by many practitioners and health insurance company policies. Earlier referral to TMS is not commonly practiced but may be non-inferior to or superior to medication switches or augmentation. Our field lacked trials that compared different modalities of treatment in parallel with TMS until recently, which is the subject of this webinar.
The core aspect of this webinar will be reviewing two very recent articles that compare TMS to antidepressant medications. We will also review basic concepts of non-inferiority trials and meta-analyses.
At the end of the presentation, attendees will be able to:
- Understand "head-to-head" trials and meta-analyses research.
- Review and understand recent comparative articles on TMS.
- Review and understand the current and future placement of TMS in the treatment algorithms of depression.
Format: On Demand Webinar
Cost: Members: $25 | Non-members $50 | Trainee Members FREE
Speaker: Mehmet Dokucu, MD, PhD, DFAPA
Dr. Dokucu is a broadly trained neuroscientist (PhD) and academic psychiatrist (MD) with expertise in Electroconvulsive Therapy, Transcranial Magnetic Stimulation, Consultation Liaison Psychiatry and Psycho-oncology. He was the founding director of the Transcranial Magnetic Stimulation program at Northwestern Medicine in Chicago. He is currently an Associate Professor of Psychiatry at Dartmouth Geisel School of Medicine and he currently directs the Mood Disorders and Interventional Psychiatry Program at Dartmouth Hitchcock Medical Center.